WCN26-3556 T Cell Metabolic Reprogramming Determines Rituximab Response in Steroid-Dependent Minimal Change Disease

Read full text Summarise with VIRAT
Authors: Eri Koshi-Ito, Yu Watanabe, Chikao Onogi, Asuka Horinouchi, Shintaro Komatsu, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama, Hiroshi I. Suzuki
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Minimal change disease (MCD) represents the predominant cause of steroid-dependent nephrotic syndrome. While rituximab (RTX) demonstrates clinical efficacy in steroid-dependent MCD through B cell depletion, the precise immunological mechanisms determining treatment responsiveness remain incompletely understood, particularly regarding secondary effects on T cell populations.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105599–105599
Publication date
25 March 2026
Language
EN